STOK 주가 차트
STOK 수입
Stoke Therapeutics Inc
$32.23
-1.46%
$-0.48
종가: Aug 10, 16:00:00 GMT-4
$32.11
-0.37%
$-0.11
프리마켓: Aug 11, 09:10:05 GMT-4
뒤로
Stoke Therapeutics Inc (STOK) 수입
최신 수익 결과: Q1 '26
보고됨: 2026-05-07
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
STOK의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Stoke Therapeutics Inc STOK의 지난 분기 매출 실적은 어땠나요?
Stoke Therapeutics Inc의 매출 추정치는 얼마인가요?
Stoke Therapeutics Inc의 수익 품질 점수는 얼마인가요?
Stoke Therapeutics Inc는 언제 수익을 보고하나요?
Stoke Therapeutics Inc의 예상 수익은 얼마인가요?
Stoke Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$32.71
시가
$32.61
일일 범위
$32.03 - $32.75
52주 범위
$11.66 - $40.22
거래량
424.5K
평균 거래량
768.1K
배당수익률
--
EPS(TTM)
-2.83
시가총액
$1.9B
STOK란 무엇인가요?
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 170 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
